Combined Use of Bevacizumab + Interferon A-2 α in the Treatement of Patients with Disseminated Kidney Cancer in Comparison with an Active Monitoring Group ; Использование комбинации бевацизумаб + интерферон α-2А у больных диссеминированным раком почки в сравнении с группой активного наблюдения

Συγγραφείς: K. Sh. Gantsev, A. A. Khmelevskiy, К. Ш. Ганцев, А. А. Хмелевский

Πηγή: Creative surgery and oncology; Том 8, № 4 (2018); 263-267 ; Креативная хирургия и онкология; Том 8, № 4 (2018); 263-267 ; 2076-3093 ; 2307-0501 ; 10.24060/2076-3093-2018-8-4

Θεματικοί όροι: таргетная молекулярная терапия, renal cell carcinoma, neoplasms metastasis, bevacizumab, interferon-alfa, immunotherapy, chemotherapy, molecular targeted therapy, почечно-клеточная карцинома, метастазы, бевацизумаб, интерферон, иммунотерапия, химиотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/344/314; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2017 г.: заболеваемость и смертность. М.; 2018. 250 с.; Алексеев Б.Я. Метастатический рак почки: выбор терапии первой линии. Онкоурология. 2014;10(3):43-8. DOI:10.17650/1726-9776-2014-10-3-43-48; Shinohara N., Obara W, Tatsugami K., Naito S., Kamba T., Taka-hashi M., et al. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015;106(5):618-26. DOI:10.1111/cas.12646; Motzer R.J., Jonasch E., Agarwal N., Bhayani S., Bro W.P., Chang S.S., et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017;15:804-34. DOI:10.6004/jnccn.2017.0100; Powles T., Albiges L., Staehler M., Bensalah K., Dabestani S., Giles R.H., et al. Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2018;73(3):311-5. DOI:10.1016/j.eururo.2017.11.016; Anselmo Da Costa I., Rausch S., Kruck S., Todenhofer T., Stenzl A., Bedke J. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where will we go? Expert Rev Anticancer Ther. 2017;17(4):357-68. DOI:10.1080/14737140.2017.1292138; Escudier B., Albiges L. Anti-VEGF and VEGFR monoclonal antibodies in RCC. In: Bukowski R., Figlin R.A., Motzer R. (editors). Renal cell carcinoma: molecular targets and clinical applications. Springer; 2015. P. 237-52.; Thomas L., Lai S.Y., Dong W., Feng L., Dadu R., Regone R.M. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist. 2014;19(3):251-8. DOI:10.1634/theoncologist.2013-0362; North S.A., Basappa N., Basiuk J., Bjarnason G., Breau R., Canil Ch., et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J. 2015;9(5-6):164-70. DOI:10.5489/cuaj.2894; Shen C.T., Qiu Z.L., Luo Q.Y. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer. 2014;21(2):253-61. DOI:10.1530/ERC-13-0438; Soerensen A.V., Donskov F., Hermann G.G., Jensen N.V., Petersen A., Spliid H., et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer. 2014;50 (3):553-62. DOI:10.1016/j.ejca.2013.10.010; Godo S., Yoshida Y., Kawamorita N., Mitsuzuka K., Kawazoe Y., Fujita M., et al. Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma. Intern Med. 2018;57(19):2895-900. DOI:10.2169/internalmedicine.0262-17; Powles T., Rini B. Novel agents and drug development needs in advanced clear cell renal cancer. J Clin Oncol. 2018 Oct 29:JCO2018792655. DOI:10.1200/JCO.2018.79.2655; Dorff T.B., Longmate J.A., Pal S.K., Stadler W.M., Fishman M.N., Vaishampayan U.N., et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017;123(23):4566-73. DOI:10.1002/cncr.30942; Davis I.D., Xie W., Pezaro C., Donskov F., Wells J.C., Agarwal N., et al. Efficacy of second-line targeted therapy for renal cell carcinoma according to change from baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol. 2017;71(6):970-8. DOI:10.1016/j.eururo.2016.09.047; https://www.surgonco.ru/jour/article/view/344

Διαθεσιμότητα: https://www.surgonco.ru/jour/article/view/344
https://doi.org/10.24060/2076-3093-2018-8-4-263-267

Combined Use of Bevacizumab + Interferon A-2 α in the Treatement of Patients with Disseminated Kidney Cancer in Comparison with an Active Monitoring Group

Συγγραφείς: K. Sh. Gantsev, A. A. Khmelevskiy

Πηγή: Креативная хирургия и онкология, Vol 8, Iss 4, Pp 263-267 (2019)

Θεματικοί όροι: почек новообразования, почечно-клеточная карцинома, метастазы, бевацизумаб, интерферон, иммунотерапия, химиотерапия, таргетная молекулярная терапия, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/344; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/25e4b2f9979b4d8e9474cd04117bae50

Διαθεσιμότητα: https://doi.org/10.24060/2076-3093-2018-8-4-263-267
https://doaj.org/article/25e4b2f9979b4d8e9474cd04117bae50